Published • loading... • Updated
Liver Fat Fell to Normal in 23 of 26 Adults with Obesity in Small Wegovy Post Hoc Analysis
Summary by Medical Daily
4 Articles
4 Articles
Novo Nordisk (NYSE: NVO) Wegovy Clears Liver Fat To Normal Levels In Nearly 9 Out Of 10 Obese Adults In STEP UP Trial Analysis
New data from Novo Nordisk (NYSE: NVO) shows that Wegovy reduced liver fat to normal levels in the vast majority of adults with obesity who had elevated liver fat at the start of treatment. The findings, presented at the European Association for the Study of Diabetes Annual Meeting 2026 in Milan, Italy, come from a […]
The drug semaglutide is associated with a significant reduction in liver fat in obese adults who do not have diabetes, according to an analysis presented at the 62nd Annual Congress of the European Association for the Study of Diabetes (EASD) in Milan. The data refer to participants who received Wegovy (semaglutide) in doses of 2.4 and 7.2 milligrams for 72 weeks. […]
Coverage Details
Total News Sources4
Leaning Left1Leaning Right0Center1Last UpdatedBias Distribution50% Left, 50% Center
Bias Distribution
- 50% of the sources lean Left, 50% of the sources are Center
50% Center
L 50%
C 50%
Factuality
To view factuality data please Upgrade to Premium
